한빛사 논문
Abstract
So Jin Lee1,‡, Dr. Myung Sook Huh1,‡, Seung Young Lee1,2, Solki Min1, Dr. Seulki Lee1, Dr. Heebeom Koo1, Dr. Jun-Uk Chu1, Dr. Kyung Eun Lee1, Dr. Hyesung Jeon1, Dr. Yongseok Choi2, Dr. Kuiwon Choi1, Dr. Youngro Byun3, Dr. Seo Young Jeong4, Dr. Kinam Park5, Dr. Kwangmeyung Kim1,*, Dr. Ick Chan Kwon1,*
1Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, 39-1 Hawolgok-dong, Seongbuk-gu, Seoul 136-791 (Korea)
2School of Life Science and Biotechnology, Korea University (Korea)
3Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University (Korea)
4Department of Life and Nanopharmaceutical Science, Kyung Hee University (Korea)
5Departments of Biomedical Engineering and Pharmaceutics, Purdue University (USA)
‡These authors contributed equally to this work.
*To whom correspondence may be addressed.
This study was funded by the Global Research Laboratory (GRL) Project, the Fusion Technology Project (2010-50201), and the Intramural Research Program (Global RNAi Initiative) of KIST.
The condensed version: Thiolated glycol chitosan can form stable nanoparticles with polymerized siRNAs through charge-charge interactions and self-cross-linking (see scheme). This poly-siRNA/glycol chitosan nanoparticles (psi-TGC) provided sufficient in vivo stability for systemic delivery of siRNAs. Knockdown of tumor proteins by psi-TGC resulted in a reduction in tumor size and vascularization.
Keywords:antitumor agents;glycol chitosan;nanoparticles;poly-siRNA;siRNA delivery
논문정보
관련 링크
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기